Skip to main content
SpringerLink
Log in

The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients

  • Chapter
  • First Online:
Application of Omic Techniques to Identify New Biomarkers and Drug Targets for COVID-19

Part of the book series: Advances in Experimental Medicine and Biology ((PMISB,volume 1412))

  • 465 Accesses

Abstract

Since the outbreak of the COVID-19 pandemic in December 2019, scientists worldwide have been looking for a way to control this global threat. One of the most successful and practical solutions has been the development and worldwide distribution of the COVID-19 vaccines. However, in a small percentage of cases, vaccination can lead to de novo development or exacerbation of immune or inflammatory conditions such as psoriasis. Due to the immunomodulatory nature of this disease, people affected by psoriasis and other related skin conditions have been encouraged to receive COVID-19 vaccines, which are immunomodulatory by nature. As such, dermatological reactions are possible in these patients, and cases of onset, exacerbation or change in the type of psoriasis have been observed in patients administered with COVID-19 vaccines. Considering the rarity and minor nature of some of these cutaneous reactions to COVID-19 vaccination, there is a general consensus that the benefits of vaccination outweigh the potential risks of experiencing such side effects. Nevertheless, healthcare workers who administer vaccines should be made aware of the potential risks and advise recipients accordingly. Furthermore, we suggest careful monitoring for potentially deleterious autoimmune and hyperinflammatory responses using point-of-care biomarker monitoring.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. El Zowalaty ME,Järhult JD (2020) From SARS to COVID-19: A previously unknown SARS-related coronavirus (SARS-CoV-2) of pandemic potential infecting humans–Call for a One Health approach. One Health 9:100124. https://doi.org/10.1016/j.onehlt.2020.100124

    Article  PubMed  PubMed Central  Google Scholar 

  2. Lai CC, Shih TP, Ko WC, et al (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 55(3):105924. https://doi.org/10.1016/j.ijantimicag.2020.105924

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kempuraj D, Selvakumar GP, Ahmed ME, et al. (2020) COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist 26(5–6):402–414

    Article  CAS  PubMed  Google Scholar 

  4. Coronavirus (COVID-19) Vaccinations. https://ourworldindata.org/covid-vaccinations. Accessed October 18, 2022

  5. Lazarus JV, Wyka K, White TM, et al (2022) Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. Nat Commun 13(1):3801. https://doi.org/10.1038/s41467-022-31441-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mushtaq HA, Khedr A, Koritala T, et al (2022) A review of adverse effects of COVID-19 vaccines. Infez Med. 30(1):1–10

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Rahman MM, Masum MHU, Wajed S, Talukder A (2022) A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. Virusdisease 33(1):1–22. https://doi.org/10.1007/s13337-022-00755-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Chi WY, Li YD, Huang HC, Chan TEH, et al (2022) COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci 29(1):82. https://doi.org/10.1186/s12929-022-00853-8

    Article  PubMed  PubMed Central  Google Scholar 

  9. Musumeci ML, Caruso G, Trecarichi AC, Micali G (2022) Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience. Dermatol Ther 35(1):e15177. https://doi.org/10.1111/dth.15177

    Article  CAS  PubMed  Google Scholar 

  10. Piros ÉA, Cseprekál O, Görög A, et al (2022) Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study. Dermatol Ther 35(5):e15408. https://doi.org/10.1111/dth.15408

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Seirafianpour F, Pourriyahi H, Gholizadeh Mesgarha M, et al (2022) A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. Dermatol Ther 35(6):e15461. https://doi.org/10.1111/dth.15461

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Tran TNA, Nguyen TTP, Pham NN, et al (2022) New onset of psoriasis following COVID-19 vaccination. Dermatol Ther 35(8):e15590. https://doi.org/10.1111/dth.15590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chhabra N, C AG (2022) A case of de novo annular-plaque type psoriasis following Oxford-AstraZeneca COVID-19 vaccination. Curr Drug Saf.. https://doi.org/10.2174/1574886317666220613163327

  14. Shakoei S, Kalantari Y, Nasimi M, et al (2022) Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases. Dermatol Ther 35(8):e15651. https://doi.org/10.1111/dth.15651

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Brunasso AMG, Massone C (2020) Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID-19 emergency in a tertiary center in Italy. Dermatol Ther 33(4):e13495. https://doi.org/10.1111/dth.13695

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Buhl T, Beissert S, Gaffal E, et al (2020) COVID-19 and implications for dermatological and allergological diseases. J Dtsch Dermatol Ges 18(8):815–824

    PubMed  PubMed Central  Google Scholar 

  17. Drenovska K, Schmidt E, Vassileva S (2020) Covid-19 pandemic and the skin. Int J Dermatol 59(11):1312–1319

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Molaee H, Allahyari F, Emadi SN, et al (2021) Cutaneous manifestations related to the COVID-19 pandemic: a review article. Cutan Ocul Toxicol 40(2):168–174

    Article  CAS  PubMed  Google Scholar 

  19. Krueger JG, Bowcock A (2005) Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 Suppl 2(Suppl 2):ii30-6. https://doi.org/10.1136/ard.2004.031120

  20. Hari G, Kishore A, Karkala SRP (2022) Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached? Eur J Pharmacol 929:175147. https://doi.org/10.1016/j.ejphar.2022.175147

    Article  CAS  PubMed  Google Scholar 

  21. Al-Beltagi M, Saeed NK, Bediwy AS (2022) COVID-19 disease and autoimmune disorders: A mutual pathway. World J Methodol 12(4):200–223

    Article  PubMed  PubMed Central  Google Scholar 

  22. Rodríguez Y, Rojas M, Beltrán S, et al (2022) Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. J Autoimmun 132:102898. https://doi.org/10.1016/j.jaut.2022.102898

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Darmarajan T, Paudel KR, Candasamy M, et al (2022) Autoantibodies and autoimmune disorders in SARS-CoV-2 infection: pathogenicity and immune regulation. Environ Sci Pollut Res Int 29(36):54072–54087

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. World Health Organization; Global Report on Psoriasis (2016). https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf.psoriasis?sequence=1. Accessed October 18, 2022

  25. Mayo Clinic; Psoriasis; Treatment; Oral or Injected Medications. https://www.mayoclinic.org/diseases-conditions/psoriasis/diagnosis-treatment/drc-20355845#:~:text=Options%20include%20apremilast%20(Otezla)%2C,)%20and%20certolizumab%20(Cimzia). Accessed October 19, 2022

  26. Di Lernia V (2020) Antipsoriatic treatments during COVID-19 outbreak. Dermatol Ther 33(4):e13345. https://doi.org/10.1111/dth.13345

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Abdelmaksoud A, Goldust M, Vestita M (2020) Comment on "COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action". Dermatol Ther 33(4):e13360. https://doi.org/10.1111/dth.13360

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Bardazzi F, Loi C, Sacchelli L, Di Altobrando A (2020) Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. J Dermatolog Treat 31(4):320–321

    Article  CAS  PubMed  Google Scholar 

  29. Megna M, Ruggiero A, Marasca C, Fabbrocini G (2020) Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat 31(4):328–329

    Article  CAS  PubMed  Google Scholar 

  30. Megna M, Napolitano M, Patruno C, Fabbrocini G (2020) Biologics for psoriasis in COVID-19 era: What do we know? Dermatol Ther 33(4):e13467. https://doi.org/10.1111/dth.13467

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Naldi L (2021) Risk of infections in psoriasis. A lesson to learn during the SARS-CoV-2 pandemic. Br J Dermatol 184(1):6. https://doi.org/10.1111/bjd.19190

  32. Kara Polat A, Oguz Topal I, Karadag AS, et al (2021) The impact of COVID-19 in patients with psoriasis: A multicenter study in Istanbul. Dermatol Ther 34(1):e14691. https://doi.org/10.1111/dth.14691

    Article  CAS  PubMed  Google Scholar 

  33. Gisondi P, Facheris P, Dapavo P, et al (2020) The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol 183(2):373–374

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Carugno A, Gambini DM, Raponi F, et al (2020) COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy. J Am Acad Dermatol 83(1):292–294

    Article  CAS  PubMed  Google Scholar 

  35. Damiani G, Pacifico A, Bragazzi NL, Malagoli P (2020) Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther 33(5):e13475. https://doi.org/10.1111/dth.13475

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Gananandan K, Sacks B, Ewing I (2020) Guttate psoriasis secondary to COVID-19. BMJ Case Rep 13(8):e237367. https://doi.org/10.1136/bcr-2020-237367

    Article  PubMed  PubMed Central  Google Scholar 

  37. Rouai M, Rabhi F, Mansouri N, et al (2021) New-onset guttate psoriasis secondary to COVID-19. Clin Case Rep 9(7):e04542. https://doi.org/10.1002/ccr3.4542

    Article  PubMed  PubMed Central  Google Scholar 

  38. Penso L, Dray-Spira R, Weill A, et al (2022) Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France. Br J Dermatol 186(1):59–68

    Article  CAS  PubMed  Google Scholar 

  39. Wack S, Patton T, Ferris LK (2021) COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. J Am Acad Dermatol 85(5):1274–1284

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Geisen UM, Berner DK, Tran F, et al (2021) Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 80(10):1306–1311

    Article  CAS  PubMed  Google Scholar 

  41. Simon D, Tascilar K, Fagni F, et al (2021) SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis 80(10):1312–1316

    Article  CAS  PubMed  Google Scholar 

  42. Skroza N, Bernardini N, Tolino E, et al (2021) Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience. J Clin Med 10(15):

    Google Scholar 

  43. Damiani G, Allocco F, Malagoli P (2021) COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers. Clin Exp Dermatol 46(6):1106–1108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Gelfand JM, Armstrong AW, Bell S, et al (2021) National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol 84(5):1254–1268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Elamin S, Hinds F,Tolland J (2022) De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine. Clin Exp Dermatol 47(1):153–155

    Article  CAS  PubMed  Google Scholar 

  46. Nagrani P, Jindal R, Goyal D (2021) Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): Report of two cases. Dermatol Ther 34(5):e15085. https://doi.org/10.1111/dth.15085

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Song WJ, Lim Y, Jo SJ (2022) De novo guttate psoriasis following coronavirus disease 2019 vaccination. J Dermatol 49(1):e30–e31

    Article  CAS  PubMed  Google Scholar 

  48. Lehmann M, Schorno P, Hunger RE, et al (2021) New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report. J Eur Acad Dermatol Venereol 35(11):e752–e755

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Ricardo JW, Lipner SR (2021) Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. JAAD Case Rep 1718–1720

    Google Scholar 

  50. Gunes AT, Fetil E, Akarsu S, et al (2015) Possible Triggering Effect of Influenza Vaccination on Psoriasis. J Immunol Res 2015:258430. https://doi.org/10.1155/2015/258430

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Wu PC, Huang IH, Wang CW, et al (2022) New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review. Am J Clin Dermatol 23(6):775–799

    Article  PubMed  PubMed Central  Google Scholar 

  52. Krajewski PK, Matusiak Ł, Szepietowski JC (2021) Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol 35(10):e632–e634

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Durmaz I, Turkmen D, Altunisik N,Toplu SA (2022) Exacerbations of generalized pustular psoriasis, palmoplantar psoriasis, and psoriasis vulgaris after mRNA COVID-19 vaccine: A report of three cases. Dermatol Ther 35(4):e15331. https://doi.org/10.1111/dth.15331

    Article  CAS  PubMed  Google Scholar 

  54. Perna D, Jones J, Schadt CR (2021) Acute generalized pustular psoriasis exacerbated by the COVID-19 vaccine. JAAD Case Rep 17:1–3

    Article  PubMed  PubMed Central  Google Scholar 

  55. Phuan CZY, Choi EC-E,Oon HH (2022) Temporary exacerbation of pre-existing psoriasis and eczema in the context of COVID-19 messenger RNA booster vaccination: A case report and review of the literature. JAAD International 6:94–96

    Article  PubMed  Google Scholar 

  56. Mieczkowska K, Kaubisch A,McLellan BN (2021) Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor. Dermatol Ther 34(5):e15055. https://doi.org/10.1111/dth.15055

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Bostan E, Elmas L, Yel B,Yalici-Armagan B (2021) Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: A report of two cases. Dermatol Ther 34(6):e15110. https://doi.org/10.1111/dth.15110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Fang WC, Chiu LW,Hu SC (2021) Psoriasis exacerbation after first dose of AstraZeneca coronavirus disease 2019 vaccine. J Dermatol 48(11):e566–e567

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Koumaki D, Krueger-Krasagakis SE, et al (2022) Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre. J Eur Acad Dermatol Venereol 36(6):e411–e415

    Article  CAS  PubMed  Google Scholar 

  60. Wei N, Kresch M, Elbogen E,Lebwohl M (2022) New onset and exacerbation of psoriasis after COVID-19 vaccination. JAAD Case Reports 19:74–77

    Article  PubMed  Google Scholar 

  61. Sotiriou E, Tsentemeidou A, Bakirtzi K, Lallas A, Ioannides D,Vakirlis E (2021) Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. J Eur Acad Dermatol Venereol 35(12):e857–e859

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Megna M, Potestio L, Gallo L, Caiazzo G, Ruggiero A,Fabbrocini G (2022) Reply to “Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre” by Sotiriou E et al. Journal of the European Academy of Dermatology and Venereology 36(1):e11–e13

    Google Scholar 

  63. Huang YW, Tsai TF (2021) Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center. Front Med (Lausanne) 8:812010. https://doi.org/10.3389/fmed.2021.812010

    Article  PubMed  Google Scholar 

  64. Onsun N, Kaya G, Işık BG,Güneş B (2021) A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report. Health Promot Perspect 11(2):261–262

    Article  PubMed  PubMed Central  Google Scholar 

  65. Piccolo V,Russo T,Mazzatenta C,Bassi A,Argenziano G,Cutrone M et al. (2022) COVID vaccine-induced pustular psoriasis in patients with previous plaque type psoriasis. J Eur Acad Dermatol Venereol 36(5):e330–e332

    Article  CAS  PubMed  Google Scholar 

  66. Quattrini L, Verardi L, Caldarola G, Peluso G, De Simone C,D’Agostino M (2021) New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flare-up after Sars-Cov-2 vaccination. J Eur Acad Dermatol Venereol 35(11):e727–e729

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. World Health Organization; Types of COVID-19 vaccines. https://www.who.int/westernpacific/emergencies/covid-19/covid-19-vaccines. Accessed October 2022

  68. European Medicines Agency; Adapted COVID-19 vaccines. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised. Accessed October 20, 2022

  69. Sbidian E, Eftekahri P, Viguier M, et al (2014) National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines. Dermatology 229(2):130–135

    Article  PubMed  Google Scholar 

  70. Jara LJ, Vera-Lastra O, Mahroum N, et al (2022) Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? Clin Rheumatol 41(5):1603–1609

    Article  PubMed  PubMed Central  Google Scholar 

  71. Aryanian Z, Balighi K, Afshar ZM, et al (2022) COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic. J Cosmet Dermatol https://doi.org/10.1111/jocd.15448

  72. Ten Bergen LL, Petrovic A, Aarebrot AK, Appel S (2020) Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol 92(4):e12945. https://doi.org/10.1111/sji.12945

    Article  PubMed  Google Scholar 

  73. Yuan Y, Qiu J, Lin ZT, et al (2019) Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheumatol 71(6):941–951

    Article  CAS  PubMed  Google Scholar 

  74. POTS/Long Covid-diagnostics; CellTrend; https://www.celltrend.de/en/pots-cfs-me-sfn/. Accessed September 4, 2022

  75. EUROIMMUN Autoantibodies in neurological diseases. https://www.euroimmun.com/documents/Indications/Autoimmunity/Neurology/MAG_myelin_GAD/FA_1111_I_UK_A.pdf. Accessed September 4, 2022

  76. Guest PC, Abbasifard M, Jamialahmadi T, et al (2022) Multiplex Immunoassay for Prediction of Disease Severity Associated with the Cytokine Storm in COVID-19 Cases. Methods Mol Biol 2511:245–256

    Article  PubMed  Google Scholar 

  77. Zahedipour F, Guest PC, Majeed M, et al (2022) Evaluating the Effects of Curcumin on the Cytokine Storm in COVID-19 Using a Chip-Based Multiplex Analysis. Methods Mol Biol 2511:285–295

    Article  PubMed  Google Scholar 

  78. Einhorn L, Krapfenbauer K (2015) HTRF: a technology tailored for biomarker determination-novel analytical detection system suitable for detection of specific autoimmune antibodies as biomarkers in nanogram level in different body fluids. EPMA J 6:23. https://doi.org/10.1186/s13167-015-0046-y

    Article  PubMed  PubMed Central  Google Scholar 

  79. Peter H, Wienke J, Bier FF (2017) Lab-on-a-Chip Multiplex Assays. Methods Mol Biol 1546:283–294

    Article  CAS  PubMed  Google Scholar 

  80. Peter H, Mattig E, Guest PC, Bier FF (2022) Lab-on-a-Chip Immunoassay for Prediction of Severe COVID-19 Disease. Methods Mol Biol 2511:235–244

    Article  PubMed  Google Scholar 

  81. European Medicines Agency; Safety of COVID-19 vaccines. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/safety-covid-19-vaccines. Accessed October 20, 2022

  82. McMahon DE, Amerson E, Rosenbach M, et al (2021) Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol 85(1):46–55

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Català A, Muñoz-Santos C, Galván-Casas C, et al (2022) Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol 186(1):142–152

    Article  PubMed  Google Scholar 

  84. Cebeci Kahraman F, Savaş Erdoğan S, et al (2022) Cutaneous reactions after COVID-19 vaccination in Turkey: A multicenter study. J Cosmet Dermatol 21(9):3692–3703

    Article  PubMed  Google Scholar 

  85. Bostan E, Yel B, Karaduman A (2022) Cutaneous adverse events following 771 doses of the inactivated and mRNA COVID-19 vaccines: A survey study among health care providers. J Cosmet Dermatol 21(9):3682–3688

    Article  PubMed  Google Scholar 

  86. Falotico JM, Desai AD, Shah A, et al (2022) Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database. Am J Clin Dermatol 23(5):729–737

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

    Maryam Khanahmadi, Danial Khayatan & Amir Hossein Abdolghaffari

  2. GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Maryam Khanahmadi, Danial Khayatan & Amir Hossein Abdolghaffari

  3. Department of Psychiatry, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

    Paul C. Guest

  4. Laboratory of Translational Psychiatry, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

    Paul C. Guest

  5. Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil

    Paul C. Guest

  6. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Somayyeh Hashemian & Amirhossein Sahebkar

  7. Medicinal Plants Research Center, Institute of Medicinal Plants, Karaj, Iran

    Amir Hossein Abdolghaffari

  8. Department of Toxicology and Pharmacology, School of Pharmacy, and Toxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran

    Amir Hossein Abdolghaffari

  9. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

    Amirhossein Sahebkar

  10. Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

    Amirhossein Sahebkar

Authors
  1. Maryam Khanahmadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danial Khayatan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul C. Guest
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Somayyeh Hashemian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amir Hossein Abdolghaffari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amirhossein Sahebkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Campinas, Campinas, São Paulo, Brazil

    Paul C. Guest

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Khanahmadi, M., Khayatan, D., Guest, P.C., Hashemian, S., Abdolghaffari, A.H., Sahebkar, A. (2023). The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients. In: Guest , P.C. (eds) Application of Omic Techniques to Identify New Biomarkers and Drug Targets for COVID-19. Advances in Experimental Medicine and Biology(), vol 1412. Springer, Cham. https://doi.org/10.1007/978-3-031-28012-2_18

Download citation

Publish with us

Policies and ethics

Search

Navigation